Serum pro-gastrin-releasing peptide (31-98) in prostatic diseases [2] (multiple letters)

Urology

Volumn 62, Issue 1, 2003, Pages 198-199

  Yashi, Masahiro ^a   Ishikawa, Shinya ^b   Tokue, Akihika ^a   Nakagawa, Osama ^c  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Oyama Municipal Hospital   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROGASTRIN RELEASING PEPTIDE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; DISEASE MARKER; HUMAN; LETTER; NEUROENDOCRINE SYSTEM; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

EID: 0037677426     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)02574-8     Document Type: Letter

References (4)

1. O. Nagakawa Y. Furuya Y. Fujiuchi Serum pro-gastrin-releasing peptide (31-98) in benign prostatic hyperplasia and prostatic carcinoma Urology 60 2002 527 530
2. M. Yashi O. Muraishi Y. Kobayashi Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients Prostate 51 2002 84 97
3. T. Ito S. Yamamoto Y. Ohno Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence Oncol Rep 8 2001 1221 1224
4. Yashi M, Ishikawa S, Ochi M, et al : Changes in serum ProGRP (31-98) level help interpret the involvement of gastrin-releasing peptide in prostate cancer progression. Presented at the 3rd International Consultation on Prostate Cancer, UNESCO, Paris, France, June 21–23, 2002